Synergy Chc Corp SEC Filings

Synergy CHC Corp. reported Q3 2025 results. Revenue was $8,010,112 versus $7,126,333 a year ago as shipments normalized after 2024 packaging changes. Gross profit rose to $5,680,816 with a 71% margin (from 67%). Net income was $125,327 compared to $783,593 in Q3 2024, reflecting higher operating and interest costs.

For the first nine months of 2025, revenue was $24,315,642 (vs. $24,563,036), and net income increased to $2,474,827 (vs. $2,019,309). Cash was $1,006,489 and total assets $20.69M at September 30, 2025. Total liabilities were $28.94M, and stockholders’ deficit improved to $(8.25)M.

The company refinanced with a $17.5M term loan at Term SOFR + 8.5% maturing in 2029, repaid legacy debts (including $10.0M to a shareholder-lender) and recorded debt settlement gains. In August 2025, it completed an IPO, issuing 1,750,000 shares for net proceeds of $3,880,462. Shares outstanding were 11,251,853 as of November 12, 2025.

Synergy CHC Corp. furnished an 8-K to announce it issued a press release with financial and operating results for the quarter ended September 30, 2025. The company attached the press release as Exhibit 99.1, dated November 13, 2025, and noted the information is furnished, not filed, under the Exchange Act.

Alfred Baumeler, who serves as President and a Director of Synergy CHC Corp. (SNYR), reported a stock option grant on 09/18/2025. The grant is for 150,000 options to purchase common stock at an exercise price of $2.38 per share. The filing lists 150,000 shares beneficially owned following the transaction and records ownership as direct. The option has an expiration date shown as 09/18/2030. The grant vests one-third on the first anniversary of the grant date and the remaining two-thirds vest in equal monthly installments over the following 24 months, subject to continued service.

Jaime Fickett, identified as Chief Financial Officer of Synergy CHC Corp. (SNYR), reported a grant of a stock option on 09/18/2025. The option covers 150,000 shares of common stock with an exercise price of $2.38 per share and an expiration date shown as 09/18/2030. The filing states the full award is held directly by the reporting person following the transaction. The option vests one-third on the first anniversary of the grant and the remaining two-thirds in equal monthly installments over the subsequent 24 months, subject to continued service. The form was signed by an attorney-in-fact on 09/22/2025.

Synergy CHC Corp. (SNYR) reported a Form 4 showing a stock option grant to Kenek Brands Inc., which is controlled by reporting person Jack Ross, the company's CEO and Chairman. The derivative award is a 750,000-share option with an exercise price of $2.38, recorded on 09/18/2025. The filing states the option vests one-third on the first anniversary of grant and the remaining two-thirds in equal monthly installments over the following 24 months, subject to continued service. The reporting person disclaims direct ownership; the shares are owned directly by Kenek Brands Inc., making Ross an indirect beneficial owner. The Form is signed by counsel on 09/22/2025.

Synergy CHC Corp. ("Synergy" or "SNYR") is offering 1,750,000 shares of common stock with associated underwriter warrants and an overallotment option. For the six months ended June 30, 2025, net revenue was $16.3 million, down 6% versus the prior-year period; FOCUSfactor comprised ~86% of revenue while Flat Tummy was ~14%. For the same period Synergy reported net income of $2.3 million and EBITDA of $5.8 million, representing year-over-year changes of +90% and +67%, respectively. Historic FOCUSfactor annual revenue declined from $37.2 million (2023) to $30.8 million (2024). As of June 30, 2025 the company had a working capital surplus of $12.4 million and an as‑adjusted net tangible book value per share after the offering of $(0.71), producing stated immediate dilution to new investors of $3.21 per share.